Online inquiry

IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9040MR)

This product GTTS-WQ9040MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FLT1 gene. The antibody can be applied in Colon Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001159920.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2321
UniProt ID P17948
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9040MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8626MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ1520MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-011
GTTS-WQ14764MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ1570MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ2630MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ12691MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ8011MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ1611MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW